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For patients who do not have a matched sibling
donor or a volunteer matched unrelated donor, or
when there is not enough time to line up a donor due
to the rapid progression of the patient’s disease, there
are two rapidly available alternative stem cell donor
sources: a haploidentical transplantation from a three-
locus mismatched family member (parents, siblings,
or children of the patients) [1,2] or an unrelated
cryopreserved umbilical cord blood (CB) from a CB
bank [3].
Until the advent of large unrelated donor panels,
allogeneic stem cell transplants (SCT) using less than
fully matched related donors were sporadically per-
formed in situations where the risks of a mismatched
transplant were matched by those of the underlying
disease. With the availability of better than half-
matched unrelated donors and the use of umbilical
cord blood stem cell transplants (CBT) from 1990,
the place of haploidentical-related SCT has become
defined as an alternative to CBT when a fully matched
donor is unavailable. The choice of CB versus haplo
donor in this situation is worthy of debate. Practice
around the world varies: for example, in the United
States, CBT predominate. In contrast, curiously, in
Europe, CBTwere largely pioneered in countries speak-
ing romance languages whereas teutonic language–
speaking countries have been slow to adopt CBT.
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Introduction
CBT were initially performed with related donors.
Since then, a global network ofCBbanks and transplant
centers has been established with a common inventory.
An estimated 600,000 CB have been banked and more
than 20,000 units have been distributed worldwide.
CB banks have established criteria for standardization
of CB collection, processing, and cryopreservation
[4,5]. CBT have now become one of the most
commonly used source of hematopoietic stem cells
(HSCs) for allogeneic transplantation for adults and
children with life-threatening hematological diseases
[3]. Several studies have shown that the number of cells
is themost important factor for engraftmentwhile some
degree of HLA mismatch is acceptable [5,6]. The
number of adult CBTs has been increasing in recent
years because of the success of using double CB
transplants and reduced-intensity conditioning (RIC)
[7,8]. These approaches reduce early regimen-related
toxicity, increase survival, andextend transplant accessi-
bility for older adults and those with significant comor-
bidities. Indeed, in a retrospective Eurocord-Center for
International Blood and Marrow Transplant Research
(CIBMTR) study in adults with leukemia, leukemia-
free survival after mismatched CBT, or 1-2 antigen
mismatched peripheral blood or bone marrow trans-
plants, was comparable [9].
Advantages
Immediate availability
The great advantage of CBT is the massive world-
wide ‘‘off-the-shelf’’ availability of CB, bringing with it
an ever increasing ability to find well-matched, good-
quality units. The CB banks are now an important
source for rareHLAhaplotypes from ethnicminorities
[10]. After HLA typing and infectious disease testing,
cord blood can be kept in liquid nitrogen for moreS89
S90 Biol Blood Marrow Transplant 17:S89-S93, 2011J. Barrett et al.than 20 years, and CB collection does not represent
a risk for the donor or the mother [4].
Favorable alloreactivity
Graft-versus-host disease (GVHD) from CBT has
been shown to be less than comparably mismatched
peripheral blood stem cell transplants. However,
CBTmay confer a graft-versus-leukemia (GVL) effect
with a diminished risk of relapse in malignant diseases.
CBT are typically 5/6 or 4/6 matched with the recip-
ient. The role of HLA mismatches is still unclear.
Most transplants have been selected on antigen typing
for HLA class I and allelic typing for class II. In
malignant diseases, HLA mismatching is partially
overcome by increasing the cell number: GVHD in-
creases with more mismatches, but leukemic relapse
decreases, with a consequent benefit for leukemia-
free survival.Disadvantages
Single one-time availability
CBT have been limited by the unique nature of the
cell product. No opportunity exists for donor lympho-
cyte infusion in case of leukemic relapse, except when
the donor is anHLA identical sibling. Thus, transplant
strategies must be designed around the single use of
a small cell product.
Variable quality and quantity
Regulated operating procedures by the Founda-
tion for the Accreditation of Cellular Therapy (FACT)
and Netcord have done much to improve CB unit
quality, and increasing bank sizes has facilitated selec-
tion only of units with good viability and stem cell
numbers [11].
Slow hematopoietic and immune recovery
Low stem cell doses increase the risk of graft
failure and contribute to slow engraftment. A mini-
mum number of 3.7  107 nucleated cells or 1  105
CD341 cells are necessary for optimal engraftment
[12]. Immune reconstitution is delayed because of
the immaturity of the newborn immune system. This
immaturity particularly impacts on the problem of
prolonged cytomegalovirus (CMV) reactivation in at-
risk recipients [13].
Donor-derived malignancy
Several studies have identified an increased risk
of Epstein-Barr virus–associated lymphoproliferative
disorder (EBV-LPD) in recipients of CB because of
the potential that EBV in the recipient can attack the
EBV-na€ıve immune system of the graft [14]. It is also
possible that CB SCT have a greater risk of developingacute myeloblastic leukemia (AML) in the donor, but
data are scanty [15].
New Developments Addressing Current CBT
Limitations
Improving hematopoietic engraftment
In addition to the use of two cord blood units, other
methods under investigation include ex vivo stem cell
expansion [16], intrabone infusion [17], ex vivo expan-
sion with mesenchymal stromal cells, cytokine cock-
tails or homing factors, and coinfusion of CB with
mesenchymal stromal cells [18].
Generation of third-party immune cells
NK cells and regulatory T cells both have the po-
tential to exert their effect across histocompatibility
barriers, at least for a short period. It is therefore pos-
sible to use CB units as a source of NK cells for adop-
tive transfer to prevent or treat relapsed leukemia [19].
Antigen-specific T cells
Even small fractions of the lymphocytes in CB
units can serve as a source for in vitro expansion of T
cells specific for virus or tumor antigens to use in
adoptive transfer as potent tumor- or viral-specific
cytotoxic T cells [20].HAPLOIDENTICAL STEM CELL
TRANSPLANTATION
Introduction
Haploidentical SCT have been performed sporad-
ically for over 30 years, but despite the potential benefit
of a strong GVL effect, the risk of severe GVHD has
been a deterrent forwidespread application of the tech-
nique.Haplo SCT typically involve intensive immuno-
suppression to permit engraftment with either T cell
depletion or intensive immunosuppression to prevent
GVHD from the mismatched transplant. This type of
transplant has found a place in treatment of high-risk
malignancies in patients of all ages and also in treat-
ment of some nonmalignant diseases in children who
tolerate mismatched SCT better.
Advantages of Haplo SCT
Immediate availability
A highly motivated donor is already present when
the patient is diagnosed with a disease that might
only be cured by SCT. Bone marrow or peripheral
stem cells can be collected, depending on the prefer-
ence of the transplant center.
Megadoses of stem cells can be collected by repeated
mobilization cycles in order to ensure safe engraftment
and better outcome [21]. There are opportunities to
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cell mobilization to examine its impact on transplant
outcome [22].
Donor selection
There may be opportunities to select a donor with
favorable killer immunoglobulin-like receptors (KIR)
phenotypes with enhanced natural killer (NK) allor-
eactivity conferring greater GVL effects in adults
with AML [23].
Graft manipulation
To prevent GVHD, manipulation of the graft to
deplete T-lymphocytes can be performed: Techniques
include CD341 positive selection [2], CD3 depletion
[24], CD3/CD19 depletion, or other lymphocyte sub-
sets, methods to reduce the number of alloreactive
T-lymphocytes and adoptive therapy with NK cells
or tumor or viral-specific T cells [25,26].Disadvantages of Haplo SCT
Delayed immune recovery
Haplo SCT confer a high rate of often lethal infec-
tious complications [1], especially in adult patients fol-
lowing SCTwith CD341 positively selected stem cells
[2,27]. By changing the method of T cell–depletion
from CD341 positive selection to CD3/19 negative
depletion [28], the infectious complications and the
rate of transplant-related mortality (TRM) has been
reduced in both children [29] and adults [30]. Never-
theless, especially in adults, current T cell-depletion
techniques (CD341 selection or CD3/19 depletion)
additional strategies to accelerate immune reconstitu-
tion are under investigation.Whether giving unmanip-
ulated SCT [31], granulocyte-colony stimulating
factor (G-CSF)-primed bone marrow plus peripheral
stem cells [32], or unmanipulated SCTwith posttrans-
plant cyclophosphamide [33] will be associated with an
accelerated reconstitution of a functional immune sys-
tem is not yet established in prospective clinical trials.Developments in Haplo SCT
Relapse prevention
Donor-derived lymphocyte infusions, NK cells
[34], genetically modified T-lymphocytes [35], minor
histocompatibility antigen (mHA)-specific T-lympho-
cytes [36] or tumor specific T-lymphocytes [37] adop-
tively transferred after transplant are all strategies
under investigation. The haploidentical donor could
also be vaccinated with viral antigens or leukemia- or
tumor-specific antigens prior to stem cell collection to
transfer immunological memory to the patient.GVHD prevention and enhancement of immune
reconstitution
RegulatoryCD41/CD251T-lymphocytes isolated
from the donor can be infused after transplantation
in combination with DLI [38]. Donor mesenchymal
stromal cells can also be used to treat GVHD [18] or
to ensure engraftment [39].
Prevention of infection
Recently established methods for the isolation of
donor-derived virus-specific T-lymphocytes permit
the treatment of chemotherapy-refractory and life-
threatening infections with cytomegalovirus [40], ade-
novirus, EBV [41], or fungi [42].
Posttransplant monitoring of chimerism
After transplantation, the HLA disparity between
donors and recipients, especially in certain HLA class
I alleles, allows in most of the patients a rapid and sen-
sitive differentiation of the lymphocytes and other cell
subsets between donor and recipient cells in peripheral
blood or bone marrow by flow cytometric analysis of
donor- and recipient-specific HLA expression, thus
allowing the detection of residual recipients’ hemato-
poietic cells, and the identification of impending
relapse, permitting rapid recourse to DLI or adoptive
transfer of leukemia-specific T cells or NK cells.CONCLUSION
Both CBT and haplo SCT represent important
strategies tomake SCTavailable for the patientwithout
a fullymatched donor. Although the reasons for a trans-
plant center to select one or the other strategy depend
on the specific expertise and familiarity with one or
the other approach, the different advantages and
disadvantages of CBT versus haplo SCT make them
complementary. Following the introduction of CBT
as a viable alternative stem cell source, the learning
curve has been steep, and new strategies are further im-
proving outcome, with the possibility of better match-
ing from larger CB banks, stem cell expansion [16],
and T cell and NK lymphocyte expansion [43]. For
haplo SCT, new strategies to confer donor T cell im-
munity without causing GVHD are being developed
[44]. As new outcome data from these transplant strate-
gies become available, we should anticipate swings in
favor of one or the other approach. But caveat lector!
The arguments presented in this debate are time-
sensitive: transplant approaches combining haplo SCT
with cord are being explored. Such double cord
T cell–depleted haplo SCT grafts can achieve rapid he-
matologic recovery of the T cell–depleted haplo SCT
followed by the slower engraftment of the cord blood
that replaces thehaplo SCTas the cordblood immunity
S92 Biol Blood Marrow Transplant 17:S89-S93, 2011J. Barrett et al.is established.This approachhas thepotential benefit of
overcoming the problems of slow hematopoietic recov-
ery of the cord blood while compensating with cord
blood immune function for the inevitable immune
deficiency associated with the haplo SCT [45]. If this
strategy proves beneficial, debates over the value of
CBT and haplo SCT may be rendered obsolete.ACKNOWLEDGMENTS
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